Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

Trial ID or NCT#

NCT02112838

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy

Official Title

A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Renal biopsy findings consistent with IgA nephropathy - Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin II Receptor Blocker (ARB) for at least 90 days at the maximum approved (or tolerated) dose - Proteinuria > 1 gm/day at diagnosis of IgA nephropathy and Proteinuria > 0.50 gm/day at the second Screening Visit - Blood pressure controlled to ≤ 130/80 with angiotensin blockade with or without other anti-hypertensive agents
Exclusion Criteria:
  1. - Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab. - Use of > 15 mg/day prednisone (or other corticosteroid equivalent).
View All Criteria
Show Less

Investigator(s)

Richard Lafayette
Richard Lafayette
Nephrologist
Professor of Medicine (Nephrology)

Contact us to find out if this trial is right for you.

Contact

Richard Lafayette, MD
650-498-6063

View on ClinicalTrials.gov